News
Videos
Conferences
Events
Resources
Subscribe

|Videos|October 23, 2020

Outside of Treatment in Metastatic Breast Cancer

Author(s)Kristie L. Kahl

Episodes in this series

Kristie L. Kahl and Jamil Rivers

EP. 1 Treatment for Metastatic Breast Cancer

Kristie L. Kahl and Jamil Rivers

EP. 2 Joining a Clinical Trial

EP. 3 Addressing Disparities in Metastatic Breast Cancer

EP. 3 Addressing Disparities in Metastatic Breast Cancer

Kristie L. Kahl and Kate Watson

EP. 4 Outside of Treatment in Metastatic Breast Cancer

EP. 5 Talking with Your Family About Metastatic Breast Cancer

EP. 5 Talking with Your Family About Metastatic Breast Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Inluriyo, an oral therapy for ER+, HER2– metastatic breast cancer with ESR1 mutations, offers a new treatment option after prior endocrine therapy.

FDA Approves Inluriyo for ER+, HER2– Metastatic Breast Cancer

BySpencer Feldman

September 25th 2025

Image of women with pink cap.

A Patient Guide to Understanding HER2-Positive Breast Cancer

BySpencer Feldman

September 19th 2025

Martha Carlson received a diagnosis of metastatic breast cancer in 2015. Read all of Martha's blogs here!

Building Supportive Communities for Patients Navigating Cancer

ByMartha Carlson

August 14th 2025

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, review date: © stock.adobe.com.

FDA Accepts NDA for Vepdegestrant in ESR1+ Advanced Breast Cancer

BySpencer Feldman

August 12th 2025

Understanding Treatment Options for ER+/HER2–, ESR1-Mutant Metastatic Breast Cancer

ByIgor Makhlin, MD

July 24th 2025

Trending on CURE

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection

Every FDA Oncology Approval From November 2025

What Patients Should Know About EGFR Mutated Lung Cancer Treatment

What Patients With AML Need to Know About Azacitidine and Venclexta

© 2025 MJH Life Sciences^®

All rights reserved.